Skip to content

Tango Therapeutics TNGX Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$408.2M-5.0%
Amgen logo
AmgenAMGN
Gilead Sciences logo
Gilead SciencesGILD
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
Tango Therapeutics (TNGX) reported cash provided by (used in) operating activity, including discontinued operation of -$44.36M in Q1 2026.
How has Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation decreased by 6.4% year-over-year, from -$41.7M to -$44.36M.
What is the long-term trend for Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Tango Therapeutics's cash provided by (used in) operating activity, including discontinued operation has grown at a 37.2% compound annual growth rate (CAGR), from -$39.16M to -$138.89M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.